n the current issue, the study of Pierdomenico et al. 1 showed that regression of left ventricular hypertrophy (LVH) after two year's antihypertensive treatment was accompanied by a reduced risk of cardiovascular events independently of the ambulatory blood pressure during treatment. This further supports the value of using LVH regression as a surrogate end-point for morbid events in hypertension. 2 Although there is little doubt about the independence and universality of the link between increased left ventricular mass (LVM) and cardiovascular risk, the demonstration of a beneficial effect of its reduction is less clearcut. Pilot studies involving few patients and events have been published and form the subject of a positive meta-analysis by Verdecchia. 3 More recently the "echo" group in the LIFE study on a larger population of 960 patients has produced more solid evidence. 4 This study is relatively modest, 387 patients followed up for six years including 59 events, but its value lies in the demonstration that the benefit of the regression in LVM was independent of the reduction in ambulatory blood pressure during treatment. If this is confirmed on a larger scale in different populations, LVM may be regarded as an intermediate criterion. This would mean that studies of morbi-mortality requiring several thousand patients followed up for at least four to five years could be replaced by studies on regression of LVM in several hundreds of patients followed up for one or two years. This would greatly facilitate comparison of therapeutic strategies and help answer questions, which cannot be answered without the large investment in time and money on large morbi-mortality studies.
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However, to suggest that repeated echocardiographic determinations can be part of routine practice might be a little hasty. In our experience, although LVM may be a valuable criterion, its measurement by echocardiogaphy is not reliable enough. In routine practice, it is based on M mode echo recordings of the left ventricle, which has important limitations: imprecision in measurement of thickness and diameter of the left ventricle, marked dependence on tracing quality, requirement of the cube of the measurements (and of the errors inherent in the measurements) to calculate LVM, which is based on rather rough geometrical hypotheses and not always verified (dilated ventricle, asymmetric hypertrophy, etc.). This leads to poor intrapatient reproducibility with a standard deviation of differences from one examination to another of 20-30 g in published studies. Moreover the studies of reproducibility probably do not reflect real-life situations as the patients were selected for the quality of the tracings and reading were performed by trained echocardiographist in strictly controlled conditions. In the LIVE study, 5 which is closer to real-life situations by a multicentric recruitment of 505 patients with echocardiographic measurement of LVM, the standard deviation of the differences between two examinations 14 days apart was 50 g. This would indicate that in the best case scenario, it may not be justified to conclude in a significant change in LVM in a given individual for <40-60 g (maybe more in real-life conditions), while the mean alteration observed in this study after two years treatment was 34 g. In addition this reasoning excludes the subjectivity in the measurement when not carried out blind to the clinical findings and the sequence of the examinations. 6 A better method of measurement is really needed. Three-dimensional echography appears of interest, although its reproducibility has been little studied. Magnetic resonance imaging is more reproducible, but cannot really be proposed for routine monitoring of hypertensive patients.
Thus although there is increasing evidence for the value of LVM as an intermediate criterion, its exploitation will necessarily be limited to therapeutic trials for some time to come. Disclosure: The author declared no conflict of interest.
